Impact of Antenatal Betamethasone on Plasma Glucose Levels

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2010 by University of California, Irvine.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
University of California, Irvine
ClinicalTrials.gov Identifier:
NCT00585676
First received: January 2, 2008
Last updated: November 9, 2010
Last verified: November 2010
  Purpose

It is known that administration of steroids increases blood sugar levels. Administration of betamethasone is common practice during pregnancy to women at risk for preterm delivery. However, it is unknown the magnitude of the changes in glucose these women have after receiving betamethasone. The purpose of this study is to determine the magnitude and timing of the increase in blood sugar in pregnant women without diabetes who receive steroids.


Condition
Hyperglycemia

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Impact of Antenatal Betamethasone on Plasma Glucose Levels

Resource links provided by NLM:


Further study details as provided by University of California, Irvine:

Primary Outcome Measures:
  • Area under the curve of blood glucose [ Time Frame: 5 days ] [ Designated as safety issue: No ]

Estimated Enrollment: 45
Study Start Date: November 2007
Groups/Cohorts
Diabetic
Patients with Diabetes
Abnormal glucose level
Patients who were screened and had abnormal blood glucose levels
Control
Non-diabetic (normal glucose screening)

Detailed Description:

There is a substantial body of evidence that the administration of corticosteroids to patients deemed to be at risk for preterm delivery (delivery prior to 37 weeks gestation) decreases the risk of respiratory distress syndrome, intraventricular hemorrhage, and neonatal death. Current recommendations from the National Institute of Health (NIH) and the American College of Obstetricians and Gynecologists (ACOG) are that patients with pregnancies that are between 24-34 weeks gestation deemed at risk for preterm delivery receive antenatal corticosteroids. The recommended dosing is two doses of betamethasone 12 mg given 24 hours apart as an intramuscular injection. (Alternatively, dexamethasone 6 mg given intramuscularly every 6 hours for 4 doses may be administered. Betamethasone is used preferentially in our institution.)

Glucocortiocoids have a well-known effect on glucose metabolism. They increase blood glucose levels by antagonizing insulin and decreasing synthesis of insulin, thus inhibiting peripheral glucose utilization and increasing gluconeogenesis (the process by which the body produces glucose). Pregnancy is also characterized by a relative insulin resistance that results in glucose intolerance. It follows, then, that the combination of pregnancy and corticosteroids could cause significant disruption of glucose homeostasis.

Routinely in pregnancy, gestational diabetes is diagnosed by the administration of a glucose tolerance test consisting of ingestion of 50g of glucose followed by a serum glucose level one hour later. This is known as a one-hour post-glucola test. A value of 140 mg/dL is considered abnormal, and prompts administration of the 3-hour glucose tolerance test. This test consists of a fasting blood sugar, followed by serum glucose levels after a 100g oral glucose challenge at 1-, 2- and 3-hours. A profile with two or more abnormal values is considered diagnostic for gestational diabetes. In 1997 Fisher et al retrospectively compared the incidence of gestational diabetes in those patients who had received tocolytics and antenatal corticosteroids to those who did not, and found a higher incidence of both abnormal one-hour glucose screening tests and gestational diabetes in those patients who received steroids and tocolytics (medications used to try to decrease uterine contractions). However, the interval between the receipt of steroids and the administration of the glucose screening test was quite variable in this study. Shelton et al in 2002 evaluated the extent of hyperglycemia in non-diabetic patients who received multiple weekly doses of corticosteroids. They found that the fasting glucose levels increased for several days following the first course of steroids, returned to normal, and then remained persistently elevated in those patients who received three or more courses. Postprandial levels were not significantly altered. A study by Gurbuz et al in 2003 assessed the effects of betamethasone on the one-hour glucola test and found that although there was an initial effect on the screening test, this effect was transient and resolved generally one week after the administration of the second dose of betamethasone. These patients had a one-hour screening test performed prior to the administration of corticosteroids. The dosing regimen of betamethasone, however, was different from that recommended by ACOG. Thus far, no study has reported if: (1) there is significant hyperglycemia in non-diabetic patients who receive corticosteroids and (2) how the magnitude and pattern of the increase in glucose differs in patients with normal and abnormal one-hour glucolas or with diabetes. This study will be conducted as a pilot study, as there is no reports of the extent of hyperglycemia that occurs in non-diabetic patients after administration of corticosteroids to guide a sample size calculation. We will plan to obtain thirty non-diabetic subjects with fifteen diet-controlled diabetic controls for comparison. The hypothesis is that those patients that are not diabetic will not have the same extent of hyperglycemia as those who are diabetic.

  Eligibility

Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Pregnant women receiving corticosteroids

Criteria

Inclusion criteria:

  • Candidates for antenatal corticosteroids (including gestational age between 24-34 weeks)

Exclusion criteria:

  • Age less than 18 years
  • Pre-existing maternal corticosteroid or beta-mimetic tocolytic use
  • Pre-gestational diabetes mellitus, class C or greater
  • Pre-existing adrenal or pancreatic dysfunction
  • Evidence of infection
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00585676

Contacts
Contact: Christine Preslicka, RN 562 933 2755 cpreslicka@memorialcare.org

Locations
United States, California
Miller Children's Hospital Recruiting
Long Beach, California, United States, 90806
Sponsors and Collaborators
University of California, Irvine
Investigators
Principal Investigator: Michael P Nageotte, MD Miller Children's Hospital
  More Information

No publications provided

Responsible Party: Christine Preslicka, Miller Children's Hospital
ClinicalTrials.gov Identifier: NCT00585676     History of Changes
Other Study ID Numbers: 436-07
Study First Received: January 2, 2008
Last Updated: November 9, 2010
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Hyperglycemia
Glucose Metabolism Disorders
Metabolic Diseases
Betamethasone-17,21-dipropionate
Betamethasone
Betamethasone sodium phosphate
Anti-Inflammatory Agents
Therapeutic Uses
Pharmacologic Actions
Anti-Asthmatic Agents
Respiratory System Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on July 23, 2014